Full-Time

Specialty Account Manager

Posted on 10/31/2025

Deadline 11/30/25
Amgen

Amgen

10,001+ employees

Biotech company creating biologic medicines

Compensation Overview

$149.1k - $177.7k/yr

+ Base Salary + Bonus + Total Rewards Plan

New Haven, CT, USA

In Person

Up to 80% travel; field-based role requiring on-site visits within CT.

Category
Sales & Account Management (3)
, ,
Requirements
  • Bachelor's Degree and 3 years of sales experience within pharmaceutical, biotech or medical device industry or hospital sales experience OR Associate degree and 6 years of sales experience within pharmaceutical, biotech or medical device industry or hospital sales experience OR High school diploma/GED and 8 years of sales experience within pharmaceutical, biotech or medical device industry or hospital sales experience
  • Doctorate degree & 2 years of collective account management experience, sales, & commercial experience OR Master’s degree & 6 years of collective account management experience, sales, & commercial experience OR Bachelor’s degree & 8 years of collective account management experience, sales, & commercial experience OR Associate degree & 10 years of collective account management experience, sales, & commercial experience
Responsibilities
  • Develop and execute a comprehensive territory business plan to achieve and exceed sales objectives, aligned with broader commercial and strategic account goals.
  • Promote Tavneos within approved labeling in a fair, balanced, and ethical manner in accordance with corporate and industry compliance guidelines.
  • Serve as a trusted partner and disease expert to healthcare professionals by delivering meaningful, patient-centered education on disease state and product information.
  • Build and manage strong relationships with a range of stakeholders across the patient care ecosystem—including physicians, nurses, office staff, case managers, infusion centers, and caregivers.
  • Navigate and engage within diverse healthcare delivery settings such as private practices, academic institutions, IDNs, community hospitals, and specialty clinics.
  • Identify and address patient access, reimbursement, and pull-through challenges by working cross-functionally with field access teams, patient services teams, and case managers.
  • Coordinate internal matrix teams (e.g., MSLs, Market Access, Nurse Educators, TLLs) to deliver integrated, account-specific solutions that drive long-term customer engagement and product utilization.
  • Lead or support the development of referral networks and site-of-care pathways to enable seamless patient initiation and continuity of care.
  • Establish productive relationships with local and regional KOLs to expand reach and influence within the therapeutic landscape.
  • Actively contribute field insights and market intelligence to cross-functional partners and leadership to inform strategy, resource deployment, and future planning.
  • Leverage approved tools, peer education programs, and digital engagement channels to extend reach and increase impact with key stakeholders.
  • Maximize use of promotional resources and operate within assigned territory budget to support business objectives.
  • Represent the company at appropriate medical congresses, society meetings, and educational events to maintain therapeutic and competitive knowledge.
  • Complete all training and administrative responsibilities in a timely and accurate manner while upholding all company policies and compliance standards.
Desired Qualifications
  • Demonstrated success in a role involving reimbursement navigation, site of care education, and/or patient access coordination.
  • Experience promoting a product that requires extensive coordination with office staff, infusion centers, and patient services teams.
  • Prior experience working in or with Rheumatology and Nephrology strongly preferred.
  • Familiarity with Tavneos – e.g., infused therapies, buy-and-bill products, products under medical benefit highly desired.
  • Experience engaging within administrators – e.g., community practices, academic centers, IDNs, hospital systems.
  • Ability to collaborate effectively in a matrix environment, working cross-functionally with [Insert relevant roles – e.g., Market Access, Patient Services, MSLs, Nurse Educators, TLLs, Field Reimbursement].
  • Strong knowledge of payer policies, reimbursement processes, and managed markets is a plus; experience negotiating access or navigating formulary pathways is preferred for more strategic roles.
  • Proven ability to build strong customer relationships, educate on complex disease states, and adapt communication to diverse audiences.
  • Excellent interpersonal, written, and verbal communication skills; ability to communicate with both clinical and administrative stakeholders.
  • High degree of self-motivation, initiative, and adaptability in fast-paced or ambiguous environments.
  • Proficient in Microsoft Office (Word, Excel, PowerPoint, Outlook) and virtual communication tools.
  • Willingness to travel approximately up to 80%, including occasional overnight or weekend travel as needed.
  • This position is open to candidates of various backgrounds and experience levels. The role level/title will be chosen based on the candidate’s match to basic qualifications and level of experience required for this geography.

Amgen develops medicines that treat serious illnesses by using biologic therapies made from living cells. These therapies are designed to target specific disease processes, such as cancer, cardiovascular disease, and autoimmune conditions, and are produced through biotechnology methods that create proteins or antibodies. Amgen’s products are sold to patients and healthcare providers worldwide, with revenue funding ongoing research and development to discover new treatments. The company stands out by focusing on biologic medicines at a large scale and maintaining a steady pipeline of potential therapies across multiple disease areas, supported by global manufacturing and a commitment to bringing therapies to patients. Its goal is to improve patient outcomes by discovering and delivering new, effective treatments while reinvesting a significant portion of earnings into research and development.

Company Size

10,001+

Company Stage

IPO

Headquarters

Thousand Oaks, California

Founded

1980

Simplify Jobs

Simplify's Take

What believers are saying

  • Tarlatamab wins China NMPA approval May 2026 for $2B+ sales potential.
  • Q1 2026 revenues hit $8.6B with 16 brands posting double-digit growth.
  • Zai Lab partners on DLL3-ADC plus IMDELLTRA for SCLC trials.

What critics are saying

  • Prolia sales drop 34% to $727M from biosimilar competition in Q1 2026.
  • FDA warns Tavneos causes liver injuries, proposes approval withdrawal.
  • Horizon drugs Tepezza, Uplizna, Krystexxa underperform 19 months post-acquisition.

What makes Amgen unique

  • Amgen's BiTE platform establishes IMDELLTRA as second-line SCLC standard.
  • MariTide advances in Phase III obesity trials with monthly dosing.
  • UPLIZNA surges 73% post-IgG4 and gMG approvals in 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Professional Development Budget

Conference Attendance Budget

Company News

Yahoo Finance
Apr 10th, 2026
Amgen's lung cancer drug tarlatamab wins China approval, seen as $2B+ opportunity

Amgen's lung cancer drug tarlatamab has received approval from China's National Medical Products Administration, according to its development partner BeOne Medicines. The drug is a targeted immunotherapy for adults with extensive-stage small cell lung cancer that has progressed despite chemotherapy. Sold as Imdelltra in the US, tarlatamab is a bispecific antibody designed to connect cancer cells with immune cells, enabling the body's immune system to destroy the cancer. Neither Amgen nor Hong Kong-listed BeOne provided details on launch date or pricing for the Chinese market. Wall Street analysts estimate tarlatamab could generate annual sales exceeding $2 billion for Amgen.

Yahoo Finance
Apr 3rd, 2026
Amgen faces Tavneos liver injury warning as Zai Lab oncology collaboration expands IMDELLTRA pipeline

Amgen faces fresh safety concerns after the FDA warned of severe liver injuries, including vanishing bile duct syndrome, linked to Tavneos (avacopan) in late March 2026. The development adds regulatory risk to the company's investment profile. Separately, Zai Lab announced a global collaboration with Amgen to test its DLL3-targeting ADC alongside Amgen's IMDELLTRA in extensive-stage small cell lung cancer, underscoring the company's ongoing oncology expansion through external partnerships. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. However, pessimistic analysts model revenues slipping to $34.4 billion with earnings near $5.2 billion, reflecting concerns around pricing pressure, biosimilar competition and rising research and development spend alongside the new safety issues.

Yahoo Finance
Mar 30th, 2026
Amgen stock up 24% since Jim Cramer's June recommendation, beats earnings estimates

Amgen, one of the world's largest pharmaceutical companies, has seen its shares rise 24% since Jim Cramer discussed the stock on Mad Money in June 2025. The company is currently developing the weight loss drug MariTide. Amgen's shares jumped 7.5% in November 2025 after posting third-quarter results that beat analyst expectations, with $9.6 billion in revenue and $5.64 earnings per share against forecasts of $8.98 billion and $5.04 respectively. In February 2026, shares rose 8% following fourth-quarter earnings that also exceeded estimates. Cramer expressed cautious optimism about the biotech company, noting its mid-single-digit earnings growth and potential upside from its GLP-1 drug development. Whilst calling Eli Lilly his preferred GLP-1 play, Cramer said investors "could do a lot worse than Amgen" for a bargain option.

Yahoo Finance
Mar 25th, 2026
Wells Fargo lifts Amgen price target to $390, cites $20B myasthenia gravis market potential by 2036

Wells Fargo has raised its price target on Amgen to $390 from $375, maintaining an Equal Weight rating. The firm cited emerging therapies including CD20, BAFF/APRIL and next-generation complement inhibitors as potential drivers that could expand the generalized myasthenia gravis market threefold over the next decade, potentially reaching $15 billion in US sales and $20 billion globally by 2036. Separately, Jefferies initiated coverage on Amgen with a Hold rating and $350 price target on 10 March, noting the stock has gained approximately 35% over the past six months. Last month, Amgen reported fourth-quarter adjusted earnings per share of $5.29, beating the $4.76 consensus estimate, on revenue of $9.9 billion versus $9.45 billion expected.

Yahoo Finance
Mar 15th, 2026
Amgen joins TrumpRx discount scheme and lifts dividend to $2.52 per share

Amgen has announced a $2.52 per-share second-quarter dividend and joined the government-run TrumpRx platform to offer discounted drugs including Amjevita, Aimovig and Repatha. The company is also preparing for its 11 March presentation at the Leerink Global Healthcare Conference in Miami. The moves come alongside double-digit revenue and earnings per share growth in 2025 and advances in obesity and oncology programmes. However, the TrumpRx discounting could pressure net pricing as Amgen invests heavily in late-stage trials and manufacturing expansion. Amgen's narrative projects $37.4 billion revenue and $8.2 billion earnings by 2028, requiring 2.3% yearly revenue growth. Some analysts see a tougher outlook, with revenue potentially drifting towards $34.4 billion and earnings around $5.2 billion.

INACTIVE